INTERVENTION 1:	Intervention	0
Pyridoxine	Intervention	1
pyridoxine	CHEBI:16709	0-10
Arm I: Patients receive doxorubicin HCl liposome IV 40mg/m2 over 1 hour on day 1 and oral pyridoxine 100 mg twice daily on days 1-28.	Intervention	2
doxorubicin	CHEBI:28748,BAO:0000639	24-35
hour	UO:0000032	67-71
day	UO:0000033	75-78
day	UO:0000033	123-126
pyridoxine	CHEBI:16709	90-100
INTERVENTION 2:	Intervention	3
Placebo	Intervention	4
Arm II: Patients receive doxorubicin HCl liposome IV 40mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.	Intervention	5
doxorubicin	CHEBI:28748,BAO:0000639	25-36
hour	UO:0000032	68-72
day	UO:0000033	76-79
day	UO:0000033	121-124
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Diagnosis of 1 of the following:	Eligibility	1
Recurrent ovarian, fallopian tube, or peritoneal cavity cancer	Eligibility	2
recurrent	HP:0031796	0-9
fallopian tube	UBERON:0003889	19-33
peritoneal cavity	UBERON:0001179	38-55
cancer	DOID:162	56-62
Metastatic breast cancer	Eligibility	3
breast cancer	DOID:1612	11-24
Advanced endometrial cancer	Eligibility	4
endometrial cancer	DOID:1380	9-27
Planning to receive chemotherapy with doxorubicin HCl liposome at a dose of 40 mg/m^2	Eligibility	5
doxorubicin	CHEBI:28748,BAO:0000639	38-49
Hormone receptor status:	Eligibility	6
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Not specified	Eligibility	7
PATIENT CHARACTERISTICS:	Eligibility	8
patient	HADO:0000008,OAE:0001817	0-7
Sex	Eligibility	9
Not specified	Eligibility	10
Menopausal status:	Eligibility	11
Not specified	Eligibility	12
Performance status	Eligibility	13
Karnofsky 60-100%	Eligibility	14
Life expectancy	Eligibility	15
Not specified	Eligibility	16
Hematopoietic	Eligibility	17
Absolute neutrophil count  1,500/mm^3	Eligibility	18
Platelet count  100,000/mm^3	Eligibility	19
platelet count	CMO:0000029	0-14
Hemoglobin  9.0 g/dL	Eligibility	20
hemoglobin	CHEBI:35143	0-10
Hepatic	Eligibility	21
AST and ALT  2 times upper limit of normal (ULN)	Eligibility	22
Alkaline phosphatase  2 times ULN	Eligibility	23
phosphatase	GO:0016791,BAO:0000295	9-20
Bilirubin normal	Eligibility	24
Renal	Eligibility	25
Creatinine  2.0 mg/dL	Eligibility	26
creatinine	CHEBI:16737	0-10
Cardiovascular	Eligibility	27
Ejection fraction  50% by MUGA or 2-D echocardiogram	Eligibility	28
ejection fraction	CMO:0000180	0-17
No history of cardiac disease	Eligibility	29
history	BFO:0000182	3-10
disease	DOID:4,OGMS:0000031	22-29
No New York Heart Association class II-IV heart disease	Eligibility	30
heart	UBERON:0000948	12-17
heart	UBERON:0000948	42-47
heart disease	DOID:114	42-55
No clinical evidence of congestive heart failure	Eligibility	31
congestive heart failure	HP:0001635,DOID:6000	24-48
Other	Eligibility	32
Not pregnant or nursing	Eligibility	33
Fertile patients must use effective contraception during and for 3 months after completion of study treatment	Eligibility	34
No active infection requiring antibiotics	Eligibility	35
active	PATO:0002354	3-9
No history of hypersensitivity reaction attributed to a conventional formulation of doxorubicin HCl or doxorubicin HCl liposome and any of its components	Eligibility	36
history	BFO:0000182	3-10
hypersensitivity	GO:0002524,DOID:1205	14-30
doxorubicin	CHEBI:28748,BAO:0000639	84-95
doxorubicin	CHEBI:28748,BAO:0000639	103-114
No other invasive malignancy within the past 5 years except nonmelanoma or basal cell skin cancer	Eligibility	37
skin cancer	DOID:4159	86-97
PRIOR CONCURRENT THERAPY:	Eligibility	38
Biologic therapy	Eligibility	39
At least 3 weeks since prior biologic or immunologic agents for this cancer	Eligibility	40
cancer	DOID:162	69-75
Chemotherapy	Eligibility	41
Recovered from prior chemotherapy	Eligibility	42
Alopecia or neuropathy allowed	Eligibility	43
alopecia	HP:0001596,DOID:987	0-8
neuropathy	DOID:870	12-22
No prior doxorubicin HCl liposome	Eligibility	44
doxorubicin	CHEBI:28748,BAO:0000639	9-20
Other concurrent chemotherapy allowed provided palmar-plantar erythrodysesthesia is not one of the side effects of the therapy	Eligibility	45
No concurrent cytarabine, fluorouracil, liposomal daunorubicin, or capecitabine	Eligibility	46
cytarabine	CHEBI:28680	14-24
daunorubicin	CHEBI:41977	50-62
capecitabine	CHEBI:31348	67-79
No concurrent pre-medication with corticosteroids as part of the chemotherapy regimen	Eligibility	47
part of	BAO:0090002,BFO:0000050	53-60
Endocrine therapy	Eligibility	48
See Chemotherapy	Eligibility	49
At least 3 weeks since prior and no concurrent oral or topical corticosteroids	Eligibility	50
At least 1 week since prior hormonal therapy for this cancer	Eligibility	51
week	UO:0000034	11-15
cancer	DOID:162	54-60
Concurrent hormone replacement therapy allowed	Eligibility	52
hormone	CHEBI:24621	11-18
Radiotherapy	Eligibility	53
radiotherapy	OAE:0000235	0-12
At least 3 weeks since prior radiotherapy for this cancer and recovered	Eligibility	54
radiotherapy	OAE:0000235	29-41
cancer	DOID:162	51-57
Surgery	Eligibility	55
surgery	OAE:0000067	0-7
Recovered from prior surgery	Eligibility	56
surgery	OAE:0000067	21-28
Other	Eligibility	57
At least 3 weeks since prior and no other concurrent forms of pyridoxine except what is included in a multivitamin	Eligibility	58
pyridoxine	CHEBI:16709	62-72
No prior anticancer treatment that contraindicates study treatment	Eligibility	59
No concurrent amifostine or other protective agents	Eligibility	60
amifostine	CHEBI:2636	14-24
Outcome Measurement:	Results	0
Number of Participants With Palmar-plantar Erythrodysesthesia (PPE)	Results	1
Patients were monitored weekly with phone calls from the research nurse and monthly at clinic visits for overall (including pyridoxine) and specific doxorubicin HCl liposome related toxicities using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.	Results	2
pyridoxine	CHEBI:16709	124-134
doxorubicin	CHEBI:28748,BAO:0000639	149-160
cancer	DOID:162	212-218
Time frame: Treatment repeats every 4 weeks for up to 6 courses in the absence of unacceptable toxicity.	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Pyridoxine	Results	5
pyridoxine	CHEBI:16709	17-27
Arm/Group Description: Arm I: Patients receive doxorubicin HCl liposome IV 40mg/m2 over 1 hour on day 1 and oral pyridoxine 100 mg twice daily on days 1-28.	Results	6
doxorubicin	CHEBI:28748,BAO:0000639	47-58
hour	UO:0000032	90-94
day	UO:0000033	98-101
day	UO:0000033	146-149
pyridoxine	CHEBI:16709	113-123
Overall Number of Participants Analyzed: 15	Results	7
Measure Type: Number	Results	8
Unit of Measure: participants  Grade 1 HFS: 2	Results	9
Grade 2 HFS: 3	Results	10
Grade 3 HFS: 3	Results	11
Results 2:	Results	12
Arm/Group Title: Placebo	Results	13
Arm/Group Description: Arm II: Patients receive doxorubicin HCl liposome IV 40mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.	Results	14
doxorubicin	CHEBI:28748,BAO:0000639	48-59
hour	UO:0000032	91-95
day	UO:0000033	99-102
day	UO:0000033	144-147
Overall Number of Participants Analyzed: 14	Results	15
Measure Type: Number	Results	16
Unit of Measure: participants  Grade 1 HFS: 3	Results	17
Grade 2 HFS: 3	Results	18
Grade 3 HFS: 1	Results	19
Adverse Events 1:	Adverse Events	0
Total: 8/15 (53.33%)	Adverse Events	1
Blood/bone marrow  1/15 (6.67%)	Adverse Events	2
Hemorrhage/bleeding  1/15 (6.67%)	Adverse Events	3
Lymphatics  0/15 (0.00%)	Adverse Events	4
Gastrointestinal  2/15 (13.33%)	Adverse Events	5
Constitutional symptoms  0/15 (0.00%)	Adverse Events	6
Pain  0/15 (0.00%)	Adverse Events	7
pain	HP:0012531	0-4
Allergy/immunologic  0/15 (0.00%)	Adverse Events	8
Infection  1/15 (6.67%)	Adverse Events	9
Metabolic/laboratory  0/15 (0.00%)	Adverse Events	10
Neurology  1/15 (6.67%)	Adverse Events	11
Renal/genitourinary  0/15 (0.00%)	Adverse Events	12
Adverse Events 2:	Adverse Events	13
Total: 6/14 (42.86%)	Adverse Events	14
Blood/bone marrow  2/14 (14.29%)	Adverse Events	15
Hemorrhage/bleeding  0/14 (0.00%)	Adverse Events	16
Lymphatics  0/14 (0.00%)	Adverse Events	17
Gastrointestinal  0/14 (0.00%)	Adverse Events	18
Constitutional symptoms  1/14 (7.14%)	Adverse Events	19
Pain  0/14 (0.00%)	Adverse Events	20
pain	HP:0012531	0-4
Allergy/immunologic  1/14 (7.14%)	Adverse Events	21
Infection  0/14 (0.00%)	Adverse Events	22
Metabolic/laboratory  1/14 (7.14%)	Adverse Events	23
Neurology  0/14 (0.00%)	Adverse Events	24
Renal/genitourinary  0/14 (0.00%)	Adverse Events	25
